Skip to content

Artificial Intelligence Model for Growth Prediction of Ovarian Cancer Organoids

Development and Validation of Growth Prediction Model for Ovarian Cancer Organoids Based on Bright Field Image and Deep Learning

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06317610
Enrollment
100
Registered
2024-03-19
Start date
2022-01-01
Completion date
2024-05-30
Last updated
2024-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Cancer

Brief summary

The present study aims to collect early bright field image of patient-derived organoids with ovarian cancer. By leveraging artificial intelligence, this study will seek to construct and refine algorithms that able to predict growth of ovarian cancer organoids.

Interventions

OTHERgrowth prediction of ovarian cancer organoids in the frame of bright field image by leveraging AI

biopsy or puncture: Patients received biopsy or puncture to obtain tumor tissues or Malignant effusion for organoids establishment

Sponsors

Chongqing University Cancer Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* Patients must have histologically confirmed diagnosis of epithelial ovarian cancer * Patients received biopsy or puncture to obtain tumor tissues or malignant effusion * Patients voluntarily participated in the study and signed informed consent.

Exclusion criteria

* Non-epithelial ovarian cancer * No sufficient amount of tumor tissues or malignant effusion for organoids establishment.

Design outcomes

Primary

MeasureTime frameDescription
AUC of growth prediction performance using deep learning modelup to 3 yearsAUC =Area under receiver operating characteristic curve
Accuracy of growth prediction using deep learning modelup to 3 yearsAccuracy=( the number of correctly classified samples)/( the number of total samples)

Countries

China

Contacts

Primary ContactDongling Zou, MD
cqzl_zdl@163.com13657690699

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026